Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging
ID: NIH/NHLBI 115Type: BOTH
Overview

Topic

Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451753

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for a Small Business Innovation Research (SBIR) contract. The topic of the solicitation is "Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging".

The research focuses on hyperpolarized carbon 13 (13C) MRI, which allows for rapid, noninvasive, and pathway-specific investigation of dynamic metabolic and physiologic processes. This technology enables real-time in vivo investigations of metabolism in various diseases, including cancer, cardiovascular disease, lung fibrosis, inflammation, and diseases of the liver and kidney.

The SABRE (Signal Amplification by Reversible Exchange) approach is a promising modality for studying metabolism in vivo using MR techniques. It allows for the transfer of the pure singlet spin order of parahydrogen (para-H2) into a target molecule, resulting in impressive levels of polarization, short signal build-up times, low cost, and scalability. The research requires the design, implementation, and fabrication of a dedicated clinical instrument.

The solicitation accepts Fast-Track proposals and Direct-to-Phase II proposals. The anticipated awards include 1 Phase I and 1 Phase II. The budget for Phase I is $350,000 for 12 months, while Phase II has a budget of $3,000,000 for 2 years. It is recommended that proposals adhere to these budget amounts and project periods to increase the chances of funding. Proposals exceeding these amounts may not be funded.

For more information and to access the solicitation, visit the following links:

The solicitation was released on August 25, 2023, and the application due date is November 14, 2023.

Files
No associated files provided.
Similar Opportunities
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required). This solicitation aims to support Small Business Concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require Federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of unlicensed products, or administration of licensed products for unapproved indications. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, study management and oversight, safety monitoring, and regulatory activities. The project duration is not specified, but the solicitation is open until January 14, 2027. The funding specifics can be found on the grants.nih.gov website.
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) topic. This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html).
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/pa-files/PAR-24-044.html).